Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001004598 | SCV001163767 | pathogenic | Tyrosinemia type I | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001004598 | SCV003323921 | pathogenic | Tyrosinemia type I | 2022-03-09 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 13 of the FAH gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FAH-related conditions. ClinVar contains an entry for this variant (Variation ID: 813493). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the FAH protein in which other variant(s) (p.Gly404Ser) have been determined to be pathogenic (PMID: 21117323, 27814443; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |